CD33 and leukemia: And in peripheral blood, the proportion of leukemia cells (human CD33+) was significantly lower in IL-10 CAR-T treatment group than that of VEC-T treatment group [(5.550 ± 1.982) vs. (0.0780 ± 0.03323), day 28, n = 5, Fig. 4e)].